Alzheon outlined plans for a major fundraising round even after missing the Phase 3 primary endpoint for its Alzheimer’s drug candidate. The company’s move indicates it is pursuing additional capital to support next steps after the setback. For investors, the update emphasizes how Alzheimer’s development capital requirements remain high even after late-stage efficacy failures, with future strategy likely tied to additional trials, study redesign, or platform adjustments.